In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is There An ‘October Surprise’ Coming For Drug Pricing?

Executive Summary

US Congressional Democrats made Halloween the new deadline for President Biden’s Build Back Better Act, to be passed through the reconciliation process. Savings generated from prescription drug price cuts represent a key pot of money to offset the legislation’s other spending initiatives.

You may also be interested in...



Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Medicare Price Negotiation Targeting Only Post-Exclusivity Drugs Proposed By Moderate House Democrats

Legislation authorizing the US government to directly negotiate drug prices with manufacturers failed to pass in one key House committee as a trio of Democrats joined Republicans to vote against advancing the policy.   

Exclusive Interview: Biopharma And A Biden Administration

A Biden administration, if elected, would protect biopharmaceutical innovation, tackle the rising costs of cancer drugs and “promote science, without politics.”

Topics

UsernamePublicRestriction

Register

IV124914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel